Sonic Incytes to Present Data at EASL International Liver Congress™️ 2023
Velacur™️ ACE Outperforms FibroScan®️ CAP for Liver Fat Quantification We are excited to announce that clinical data from Sonic Incytes’ multi-center study will be presented at the prestigious European Association for the Study of the Liver (EASL) International Liver Congress™ 2023 in Vienna, Austria. The poster presentation highlights the comparison between point-of-care liver quantification tools, […]
Sonic Incytes Receives FDA 510(k) Clearance of AI Powered Features for Velacur™️ Liver Ultrasound
Sonic Incytes is pleased to announce they have received Food and Drug Administration (FDA) clearance for new Organ Guide and Wave Quality Detector features for Velacur™️, the Company’s liver diagnostic tool. These new artificial intelligence and machine learning (AI-ML)-based tools will improve the accuracy and performance of the device and enable less experienced medical personnel […]
Sonic Incytes Announces Clinical Trial Data Comparing Velacur™️ and FibroScan®
Sonic Incytes Medical Corp. is pleased to announce clinical data from a prospective multi-center study comparing the effectiveness of Velacur™️ and FibroScan® in measuring liver fibrosis and fat in patients with suspected NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). The results confirmed earlier findings that Velacur can effectively differentiate between various stages of […]
Sonic Incytes Announces Velacur™️ use in Madrigal Pharmaceuticals’ Open-Label Extension Clinical Trial
Sonic Incytes Medical Corp. is pleased to announce the inclusion of Velacur™️ — the first handheld 3D liver health assessment tool—in a subset of Madrigal Pharmaceutical’s MAESTRO NAFLD-1 Phase 3 Open Label Extension study of resmetirom (MGL-3196-18). As part of this Madrigal study, a subset of patients will undergo VelacurTM imaging at baseline (Day 1), Week […]
Sonic Incytes Receives Award at 2022 Digestive Disease Week Conference
The poster entitled “Accuracy of Velacur™️ AI Powered Liver Guide in Identification of Liver” presented at the Digestive Disease Week (DDW) Conference in San Diego, California received a Poster of Distinction Award. The poster reported on results from a multi-center study carried out to assess the performance of a new AI powered liver guide being […]
Register for Elastography Webinar Series
During The Liver Meeting Digital Experience™ 2020, Sonic Incytes Medical Corp. invites you to a professional development webinar series starting November 15: The Latest Advances in Elastography and its Potential in NAFLD and NASH. Join presenters Dr. Rohit Loomba (University of California, San Diego), Dr. Michael Curry (Beth Israel Deaconess Medical Center, Boston) and Moderator […]
Sonic Incytes Announces FDA Clearance and US Launch of VelacurTM to Help Manage Emerging Health Crisis
Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver health assessment tool with diagnostic accuracy comparable to Magnetic Resonance Imaging (MRI).
VelacurTM at AASLD’s The Liver Meeting 2020
Join Sonic Incytes at AASLD’s The Liver Meeting 2020, November 13-16, to find out more about how we’re creating accessible and affordable diagnostic solutions.
Visit Us at the Digital International Liver CongressTM
Sonic Incytes is proudly presenting at the EASL Digital International Liver CongressTM, August 27-29, 2020.
Genome BC Invests $1M in Breakthrough Solution for Detecting Chronic Liver Disease, Closing Off Sonic Incytes’ $3.5M Financing Round
Genome BC is pleased to announce $1 million in funding to Sonic Incytes Medical Corp., completing the company’s seed financing round of over CDN$3.5 million supported by institutional investors, angel funds and private individuals.
